Novartis Pharms. Corp. v. Alembic Pharms. Ltd. – Entresto® (Sacubitril/Valsartan)

Start
Case Name: Novartis Pharms. Corp. v. Alembic Pharms. Ltd., Civ. No. 22-1395-RGA, 2023 WL 6387975 (D. Del. Sept. 29, 2023) (Andrews, J.). Drug Product and Patent(s)-in-Suit: Entresto® (sacubitril/valsartan); U.S. Patent No. 11,096,918 (“the ’918 patent”)….
By: Robins Kaplan LLP
Previous Story

Trending in Telehealth: November 8 – 14, 2023

Next Story

[Webinar] Tech-Backed Terror: Navigating the Intersection of AI, Cryptocurrency, Money Laundering, and “Proliferation Financing” – December 1st, 1:00 pm – 2:00 pm ET